Scientists are continuing to search for cancer treatments that not only fight disease effectively but also reduce side effects and improve quality of life for patients.
A new study now suggests that an oral drug called relugolix may offer important benefits for men with prostate cancer, especially those receiving radiation therapy.
The findings, published in JAMA Oncology, have raised hopes that this newer treatment could become a safer and more convenient option for many patients.
Prostate cancer is one of the most common cancers in men worldwide. Some prostate cancers grow slowly, while others are more aggressive and can spread to other parts of the body.
One of the main ways doctors treat prostate cancer is by lowering testosterone levels because the hormone can help prostate cancer cells grow faster.
This type of treatment is called hormone therapy or androgen deprivation therapy. By reducing testosterone, doctors can slow down or stop cancer growth. Hormone therapy is often combined with radiation therapy to improve treatment results.
For many years, one of the most commonly used hormone treatments has been a drug called leuprolide. While effective, these traditional treatments can sometimes cause long-lasting side effects because testosterone levels may stay low for a long time after treatment stops.
Low testosterone can affect many parts of the body. Some men experience fatigue, loss of muscle strength, weight gain, sexual problems, mood changes, weaker bones, and increased heart risks. Because of this, researchers have been looking for treatments that control cancer well while allowing testosterone levels to recover more quickly afterward.
The new study focused on relugolix, an oral medication taken as a pill. Researchers say oral treatments are becoming increasingly important in cancer care because they are often easier and more convenient for patients compared with injections.
The research was led by Dr. Daniel Spratt, a specialist in Radiation Oncology at University Hospitals Seidman Cancer Center. The study combined data from two major international clinical trials involving 260 men with both early-stage and advanced prostate cancer.
All of the participants received relugolix along with radiation therapy. Researchers carefully monitored how well the drug lowered testosterone and how patients recovered after treatment.
The results were highly encouraging. After 24 weeks of treatment, 95% of patients reached the desired low testosterone levels needed for prostate cancer treatment. After 48 weeks, that number increased to 97%.
The researchers found that relugolix controlled testosterone just as effectively as leuprolide, which is already widely used around the world.
However, one major difference stood out. Men taking relugolix experienced much faster recovery of normal testosterone levels after stopping treatment.
This faster recovery could be very important for long-term health. Remaining in a low-testosterone state for too long may increase the risk of heart disease, bone thinning, weakness, and reduced quality of life. Faster recovery may help patients feel physically and emotionally better sooner after treatment ends.
Researchers also found that relugolix was effective at preventing prostate cancer from progressing into a more difficult form known as castration-resistant prostate cancer. This is a stage where the disease continues growing even when testosterone levels are very low.
Safety results were also positive. Only a small number of men experienced serious side effects during the study. Researchers say this could make relugolix especially useful for patients who already have heart problems or other health concerns.
The study reflects a larger trend in modern cancer treatment. Doctors are increasingly trying to personalize therapies so patients can receive effective cancer control with fewer long-term complications. Improving quality of life after treatment has become a major goal alongside improving survival.
Researchers also believe oral cancer medicines may become more common in the future because they are easier to take and may allow doctors to combine treatments in more flexible ways.
In addition to the current study, Dr. Spratt is leading another major project called the OPTYX study. This research is examining how relugolix performs in real-world medical settings outside tightly controlled clinical trials.
So far, more than 600 men have joined the OPTYX study, and researchers hope to include about 1,000 participants in total. The results may help doctors better understand how the treatment works for everyday patients with different health backgrounds and cancer stages.
Scientists say the findings are promising, but they also caution that longer follow-up studies are still needed to fully understand the long-term effects and benefits of relugolix.
Even so, many experts believe the drug represents an important step forward in prostate cancer care. By combining strong cancer control with quicker recovery and potentially fewer long-lasting side effects, relugolix may help many men live more comfortably during and after treatment.
If you care about prostate cancer, please read studies about a natural ally against prostate cancer, and supplements and keto diet can boost immunotherapy for prostate cancer.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and low-fat diet may help stop cancer growth.
The study was published in JAMA Oncology.
